Analysts Set ABIVAX Société Anonyme (NASDAQ:ABVX) Price Target at $38.67

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $38.67.

ABVX has been the subject of a number of research reports. JMP Securities reissued a “market outperform” rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP purchased a new position in shares of ABIVAX Société Anonyme during the fourth quarter worth about $144,000. Stonepine Capital Management LLC acquired a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $110,000. Shay Capital LLC acquired a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $366,000. Millennium Management LLC grew its stake in shares of ABIVAX Société Anonyme by 44.2% in the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after purchasing an additional 285,542 shares during the last quarter. Finally, Citadel Advisors LLC increased its holdings in shares of ABIVAX Société Anonyme by 83.5% in the fourth quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after purchasing an additional 389,247 shares during the period. 47.91% of the stock is currently owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Stock Performance

ABIVAX Société Anonyme stock opened at $8.08 on Monday. The stock’s fifty day moving average is $6.83 and its two-hundred day moving average is $9.14. ABIVAX Société Anonyme has a 1-year low of $5.49 and a 1-year high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.